These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15172168)

  • 1. Liposomal antisense oligonucleotides for cancer therapy.
    Siwak DR; Tari AM; Lopez-Berestein G
    Methods Enzymol; 2004; 387():241-53. PubMed ID: 15172168
    [No Abstract]   [Full Text] [Related]  

  • 2. Ribosomal protein P2: a potential molecular target for antisense therapy of human malignancies.
    Gardner-Thorpe J; Ito H; Ashley SW; Whang EE
    Anticancer Res; 2003; 23(6C):4549-60. PubMed ID: 14981896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects.
    Venugopalan P; Jain S; Sankar S; Singh P; Rawat A; Vyas SP
    Pharmazie; 2002 Oct; 57(10):659-71. PubMed ID: 12426945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The strategy of cancer gene therapy].
    Ito Y; Niitsu Y
    Tanpakushitsu Kakusan Koso; 1997 Jul; 42(10 Suppl):1780-8. PubMed ID: 9279113
    [No Abstract]   [Full Text] [Related]  

  • 5. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes.
    Fattal E; Couvreur P; Dubernet C
    Adv Drug Deliv Rev; 2004 Apr; 56(7):931-46. PubMed ID: 15066753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers.
    Jääskeläinen I; Lappalainen K; Honkakoski P; Urtti A
    Methods Enzymol; 2004; 387():210-30. PubMed ID: 15172166
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control.
    Mathis JM; Williams BJ; Sibley DA; Carroll JL; Li J; Odaka Y; Barlow S; Nathan CO; Li BD; DeBenedetti A
    J Gene Med; 2006 Sep; 8(9):1105-20. PubMed ID: 16802401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA combination therapy to stop tumor growth.
    Wickstrom E; Smith JB
    Cancer J Sci Am; 1998 May; 4 Suppl 1():S43-7. PubMed ID: 9619270
    [No Abstract]   [Full Text] [Related]  

  • 9. Oligonucleotide delivery to tumours using macromolecular carriers.
    Dass CR
    Biotechnol Appl Biochem; 2004 Oct; 40(Pt 2):113-22. PubMed ID: 15070400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
    Wang Y; Saad M; Pakunlu RI; Khandare JJ; Garbuzenko OB; Vetcher AA; Soldatenkov VA; Pozharov VP; Minko T
    Clin Cancer Res; 2008 Jun; 14(11):3607-16. PubMed ID: 18519795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides directed at cell cycle regulatory genes as strategy for restenosis therapy.
    Morishita R; Gibbons GH; Ellison KE; Nakajima M; von der Leyen H; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
    Trans Assoc Am Physicians; 1993; 106():54-61. PubMed ID: 8036745
    [No Abstract]   [Full Text] [Related]  

  • 13. 17Beta-estradiol-associated stealth-liposomal delivery of anticancer gene to breast cancer cells.
    Reddy BS; Banerjee R
    Angew Chem Int Ed Engl; 2005 Oct; 44(41):6723-7. PubMed ID: 16187396
    [No Abstract]   [Full Text] [Related]  

  • 14. Antisense therapy for cancer.
    Gleave ME; Monia BP
    Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules.
    Xu M; Lu X; Kallinteris NL; Wang Y; Wu S; von Hofe E; Gulfo JV; Humphreys RE; Hillman GG
    Curr Opin Mol Ther; 2004 Apr; 6(2):160-5. PubMed ID: 15195928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy of human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides directed against telomerase reverse transcriptase mRNA.
    Tao Z; Chen S; Wu Z; Xiao B; Liu J; Hou W
    J Laryngol Otol; 2005 Feb; 119(2):92-6. PubMed ID: 15829059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.
    Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K
    J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting VEGF in cancer therapy.
    Donovan EA; Kummar S
    Curr Probl Cancer; 2006; 30(1):7-32. PubMed ID: 16443047
    [No Abstract]   [Full Text] [Related]  

  • 19. MicroRNAs and their antagonists as novel therapeutics.
    Shomron N
    Eur J Cancer; 2009 Sep; 45 Suppl 1():388-90. PubMed ID: 19775642
    [No Abstract]   [Full Text] [Related]  

  • 20. Liquid phase synthesis and evaluation of antisense oligodeoxynucleotides to DNA polymerase alpha.
    Mazzei M; Balbi A; Sottofattori E; Abramova T; Alama A; Nicolin A
    Nucleic Acids Symp Ser; 1991; (24):298. PubMed ID: 1841355
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.